Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name FPV-CV301 + M7824 + MVA-BN-CV301 + SX-682
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
FPV-CV301 FPV-CV-301|FPV Vaccine CV301|FPV CV301|FPV CV 301 FPV-CV301 is a booster cancer vaccine derived from recombinant fowlpox virus encoding CEA and MUC-1, as well as B7-1, ICAM-1, and LFA-3 costimulatory molecules (TRICOM), which potentially induces cytotoxic T-cell response against tumor cells expressing CEA and MUC-1 (NCI Thesaurus).
M7824 Bintrafusp alfa|MSB0011359C Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 68 TGFBR2 Antibody 2 Bintrafusp alfa (M7824) is a human PD-L1 (CD274) antibody fused with transforming growth factor-beta (TGF-beta, TGFBR2) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (PMID: 29298798, PMID: 32461347).
MVA-BN-CV301 MVA-BN CV301|MVA BN CV301|MVA-BN-CV-301 MVA-BN-CV301 is a priming cancer vaccine derived from a modified vaccinia Ankara-Bavarian Nordic (MVA-BN) virus encoding CEA and MUC-1, as well as B7-1, ICAM-1, and LFA-3 costimulatory molecules (TRICOM), which potentially induces cytotoxic T-cell response against tumor cells expressing CEA and MUC-1 (NCI Drug Dictionary).
SX-682 SX682|SX 682 CXCR Antagonist 4 SX-682 is an inhibitor of the C-X-C chemokine receptor types, CXCR1 and CXCR2, resulting in reduced neutrophil chemotaxis and decreased tumor cell tumor cell migration (PMID: 31848188).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04574583 Phase Ib/II FPV-CV301 + M7824 + MVA-BN-CV301 + SX-682 Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) Recruiting USA 0


Additional content available in CKB BOOST